Clinical Trials Logo

Gray Zone Lymphoma clinical trials

View clinical trials related to Gray Zone Lymphoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05208853 Not yet recruiting - Hodgkin Lymphoma Clinical Trials

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

Start date: February 10, 2022
Phase: Early Phase 1
Study type: Interventional

This is a single-center, open label, single dose study of anti CD30 CAR-T cells injection in treatment of patients with relapsed/refractory CD30+ lymphoma.

NCT ID: NCT04860674 Not yet recruiting - Chemotherapy Effect Clinical Trials

A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma

Start date: May 1, 2021
Phase: Phase 2
Study type: Interventional

There are no standard chemotherapy regimens for relapse/refractory gray area lymphoma. The programmed cell death ligand 1 (PD-L1) encoding gene is located in 9p24.1, so it is speculated that the programmed cell death pathway plays an important role in gray area lymphoma formation by evading immune surveillance in GZL.The purpose of this study was to evaluate the efficacy and safety of PD-1 monoclonal antibody combined with ICE in the treatment of patients with relapsed/refractory gray area lymphoma.